Faint hope for Alder as Teva bucks dismal migraine trend - Vantage

Faint hope for Alder as Teva bucks dismal migraine trend  VantageAlder hopes soon to launch its migraine drug eptinezumab, and will nervously have been watching the first full quarter's sales of three similarly acting drugs.